← Back to Screener
Cabaletta Bio, Inc. Common Stock (CABA)
Price$3.67
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)59.88%
Price vs S&P 500 (4W)23.60%
VGM Score73.40
Market Capitalization$616.35M
All Metrics
Book Value / Share (Quarterly)$0.93
P/TBV (Annual)7.65x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.29
Price vs S&P 500 (YTD)61.67%
EPS (TTM)$-1.96
10-Day Avg Trading Volume3.07M
EPS Excl Extra (TTM)$-1.96
EPS (Annual)$-2.10
ROI (Annual)-123.71%
Cash / Share (Quarterly)$1.05
ROA (Last FY)-101.68%
EBITD / Share (TTM)$-1.87
ROE (5Y Avg)-68.89%
Cash Flow / Share (Annual)$-1.32
P/B Ratio5.97x
P/B Ratio (Quarterly)2.90x
Net Income / Employee (Annual)$-1,090,000
ROA (TTM)-96.46%
EPS Incl Extra (Annual)$-2.10
Current Ratio (Annual)2.77x
Quick Ratio (Quarterly)2.81x
3-Month Avg Trading Volume3.46M
52-Week Price Return97.91%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.86
52-Week High$4.23
EPS Excl Extra (Annual)$-2.10
CapEx CAGR (5Y)13.94%
26-Week Price Return75.81%
Quick Ratio (Annual)2.66x
13-Week Price Return8.62%
Total Debt / Equity (Annual)0.21x
Current Ratio (Quarterly)2.95x
Enterprise Value$523.68M
Book Value / Share Growth (5Y)-24.49%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.33
3-Month Return Std Dev90.73%
Net Income / Employee (TTM)$-1,139,100
ROE (Last FY)-149.80%
EPS Basic Excl Extra (Annual)$-2.10
Total Debt / Equity (Quarterly)0.23x
EPS Incl Extra (TTM)$-1.96
ROI (TTM)-112.56%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.55
Price vs S&P 500 (52W)69.70%
Year-to-Date Return72.60%
5-Day Price Return3.56%
EPS Normalized (Annual)$-2.10
ROA (5Y Avg)-54.58%
Month-to-Date Return26.42%
Cash Flow / Share (TTM)$-1.64
EBITD / Share (Annual)$-2.13
ROI (5Y Avg)-62.80%
EPS Basic Excl Extra (TTM)$-1.96
P/TBV (Quarterly)4.97x
P/B Ratio (Annual)1.88x
Book Value / Share (Annual)$1.12
Price vs S&P 500 (13W)-1.13%
Beta3.25x
Revenue / Share (TTM)$0.00
ROE (TTM)-131.58%
52-Week Low$1.26
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.39est. -0.41
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.19
4.19
4.19
4.19
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CABACabaletta Bio, Inc. Common Stock | — | — | B | $3.67 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary CAART technology selectively eliminates disease-causing B cells while preserving normal B cells, offering the potential for deep and durable therapeutic effects. The company's CABA platform encompasses multiple strategies applicable across a broad range of autoimmune indications.